Shots:
- AbbVie has entered into collaboration & license option agreement with ADARx to develop siRNA therapeutics across multiple disease areas, incl. neuroscience, immunology & oncology, leveraging ADARx’s RNA tech
- As per the deal, ADARx will receive $335M upfront & will be eligible to receive several billion in additional contingent payments incl. option fees, milestones, plus tiered royalties
- Collaboration will combine ADARx’s RNA discovery expertise & siRNA tech for targeted & sustained mRNA silencing with AbbVie’s expertise in antibody engineering, ADCs, & tissue delivery to enhance discovery efforts
Ref: AbbVie | Image: AbbVie & ADARx Pharmaceuticals I Press Release
Related News:- AbbVie Reports the US FDA’s BLA Submission for TrenibotulinumtoxinE (TrenibotE) to Treat Glabellar Lines
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
